All In Biotech

Drug Trial Radar · NCT07797231

Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response

A Randomized, Double-Blind, Placebo-Controlled Phase III Trial With an Open-Label Extension to Evaluate the Efficacy and Safety of TQA3605 Tablets in Chronic Hepatitis B Virus-Infected Patients With Low-Level Viremia or Suboptimal Response After at Least 12 Months of NAs Therapy

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 930 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

930

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Sep 2028

Study completion Oct 2029

Sponsor

Sponsor type
Industry
First posted
Sep 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled Phase III study with an open-label extension. The purpose is to evaluate efficacy and safety in adult patients with chronic hepatitis B virus infection who have received at least 12 months of NAs therapy, to demonstrate that TQA3605 Tablets combined with oral nucleos(t)ide analogues can improve efficacy with satisfactory safety profile compared with oral nucleos(t)ide analogues alone in this population. Approximately 930 adult patients with chronic hepatitis B virus infection who have received at least 12 months of NAs therapy are planned to be enrolled in this study.

Conditions

  • Chronic Hepatitis B

Interventions

  • TQA3605 tablets PlaceboDrug

    Placebo contains no active substance.

  • TQA3605 tabletsDrug

    TQA3605 tablets are core protein allosteric modulators

  • Entecavir dispersible tabletsDrug

    Entecavir dispersible tablets are a type of nucleoside analog antiviral drug.

  • Tenofovir Disoproxil Fumarate TabletsDrug

    Tenofovir Disoproxil Fumarate (TDF) is a nucleoside reverse transcriptase inhibitor.

  • Tenofovir Alafenamide Fumarate TabletsDrug

    Tenofovir Alafenamide Fumarate (TAF) is a nucleoside reverse transcriptase inhibitor.

  • Tenofovir Amibufenamide TabletsDrug

    Tenofovir Amibufenamide (TMF) is a phosphoramidate prodrug of tenofovir and belongs to nucleos(t)ide reverse transcriptase inhibitors.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HBV DNATime frame: 48 weeks

Locations

76 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • The First Affiliated Hospital of Ustc(Anhui Provincial Hospital)

    Hefei, Anhui, China

  • The First Affiliated Hospital of Wannan Medical College / Yijishan Hospital of Wannan Medical College

    Wuhu, Anhui, China

  • Beijing Ditan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

  • Beijing Youan Hospital,Capital Medical University

    Beijing, Beijing Municipality, China

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • The Southwest Hospital of Amu

    Chongqing, Chongqing Municipality, China

  • Chongqing University Three Gorges Hospital

    Chongqing, Chongqing Municipality, China

  • Mengchao Hepatobiliary Hospital of Fujian Medical University

    Fuzhou, Fujian, China

  • Zhongshan Hospital, Xiamen University

    Xiamen, Fujian, China

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, China

  • Gansu Wuwei Tumour Hospital

    Wuwei, Gansu, China

  • Nanhai District People's Hospital of Foshan

    Foshan, Guangdong, China

  • The Third Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Peking University Shenzhen Hospital

    Shenzhen, Guangdong, China

  • The Fifth Affiliated Hospital of Sun Yat-sen University

    Zhuhai, Guangdong, China

  • Liuzhou Worker's Hospital

    Liuzhou, Guangxi, China

  • Guizhou Provincial People's Hospital

    Guiyang, Guizhou, China

  • Affiliated Hospital of Zunyi Medical University

    Zunyi, Guizhou, China

  • Hainan Provincial People's Hospital

    Haikou, Hainan, China

  • Hebei Petro China Central Hospital

    Langfang, Hebei, China

  • Shijiazhuang Fifth Hospital

    Shijiazhuang, Hebei, China

  • The Fourth Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • Harbin Medical University, The Second Affiliated Hospital

    Harbin, Heilongjiang, China

  • Mudanjiang Kang'an Hospital

    Mudanjiang, Heilongjiang, China

  • Anyang People's Hospital

    Anyang, Henan, China

  • Luoyang Central Hospital(Luoyang Central Hospital Affiliated to Zhengzhou University)

    Luoyang, Henan, China

  • Puyang People's Hospital

    Puyang, Henan, China

  • The Sixth People's Hospital of Zhengzhou

    Zhengzhou, Henan, China

  • The first affiliated hospital of Zhengzhou university

    Zhengzhou, Henan, China

  • Jingzhou Central Hospital

    Jingzhou, Hubei, China

  • Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • The First Affiliated Hospital Of University Of South China

    Hengyang, Hunan, China

  • The General Hospital of Hunan University of Medicine

    Huaihua, Hunan, China

  • Chifeng Hospital

    Chifeng, Inner Mongolia, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China

  • The Fifth People's Hospital of Suzhou

    Suzhou, Jiangsu, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

Showing 40 of 76 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.